IN2012DN05101A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN05101A IN2012DN05101A IN5101DEN2012A IN2012DN05101A IN 2012DN05101 A IN2012DN05101 A IN 2012DN05101A IN 5101DEN2012 A IN5101DEN2012 A IN 5101DEN2012A IN 2012DN05101 A IN2012DN05101 A IN 2012DN05101A
- Authority
- IN
- India
- Prior art keywords
- igf
- seq
- antibodies
- cdr sequences
- chain cdr
- Prior art date
Links
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 2
- 101150088952 IGF1 gene Proteins 0.000 abstract 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2010021345 | 2010-01-19 | ||
| PCT/US2010/027155 WO2011090492A1 (en) | 2010-01-19 | 2010-03-12 | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN05101A true IN2012DN05101A (enrdf_load_stackoverflow) | 2015-10-23 |
Family
ID=44307101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5101DEN2012 IN2012DN05101A (enrdf_load_stackoverflow) | 2010-01-19 | 2010-03-12 |
Country Status (7)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US9958456B2 (en) | 2011-10-07 | 2018-05-01 | Baxalta Incorporated | OxMIF as a diagnostic marker |
| EP2785382B1 (en) * | 2011-12-02 | 2019-01-02 | IBC Pharmaceuticals, Inc. | Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors |
| AU2013202693B2 (en) * | 2012-04-16 | 2015-01-22 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics |
| EP3552628A1 (en) | 2012-09-07 | 2019-10-16 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
| EP3087098B1 (en) * | 2013-12-24 | 2020-04-08 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
| US10633443B2 (en) * | 2014-09-26 | 2020-04-28 | Macrogenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof |
| GB201501930D0 (en) * | 2015-02-05 | 2015-03-25 | Univ London Queen Mary | Biomarkers for pancreatic cancer |
| MA44776A (fr) | 2016-04-15 | 2019-03-06 | Immunext Inc | Anticorps anti-vista humain et leur utilisation |
| RU2770197C2 (ru) * | 2016-08-16 | 2022-04-14 | Нэшнл Инститьют Оф Эдванст Индастриал Сайенс Энд Текнолоджи | Пептид злокачественной опухоли, являющийся мишенью |
| WO2018204869A1 (en) | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
| BR112019023249A8 (pt) | 2017-05-05 | 2021-02-23 | Centre For Probe Dev And Commercialization | anticorpos monoclonais igf-1r e usos dos mesmos |
| MY206158A (en) | 2017-05-24 | 2024-12-02 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| CN111094330A (zh) | 2017-07-03 | 2020-05-01 | 转矩医疗股份有限公司 | 编码免疫刺激融合分子的多核苷酸及其用途 |
| CN113512116B (zh) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
| CN113061191B (zh) * | 2021-03-17 | 2023-03-24 | 托比康尔生物科技(武汉)有限公司 | 一种IgG样三功能抗体及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5252296A (en) | 1990-05-15 | 1993-10-12 | Chiron Corporation | Method and apparatus for biopolymer synthesis |
| US5492807A (en) | 1993-11-19 | 1996-02-20 | Santi; Daniel V. | Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease |
| US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
| US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
| US6068829A (en) | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
| US6737249B1 (en) * | 1997-08-22 | 2004-05-18 | Genentech, Inc. | Agonist antibodies |
| US7279160B2 (en) * | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| US7329745B2 (en) | 2000-06-13 | 2008-02-12 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
| WO2004009805A1 (ja) * | 2002-07-19 | 2004-01-29 | Japan Science And Technology Agency | 新規抗体酵素生産方法、新規抗体酵素、およびその利用 |
| CA2518980A1 (en) * | 2003-03-14 | 2004-09-30 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
| JP2007523956A (ja) * | 2004-02-25 | 2007-08-23 | ダナ−ファーバー キャンサー インスティテュート インク． | 腫瘍細胞増殖を阻害するための方法 |
| MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| JP5657862B2 (ja) * | 2005-07-28 | 2015-01-21 | ノバルティス アーゲー | Ｍ−ｃｓｆに対する抗体の使用 |
| EP1937851A4 (en) * | 2005-10-19 | 2010-08-25 | Ibc Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR PRODUCING BIOACTIVE GROUPS OF INCREASED COMPLEXITY AND THEIR USE |
| JP2009532027A (ja) * | 2006-03-28 | 2009-09-10 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗ｉｇｆ−１ｒ抗体およびその使用 |
| GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
| EP2274010A1 (en) * | 2008-04-11 | 2011-01-19 | Biogen Idec MA Inc. | Therapeutic combinations of anti-igf-1r antibodies and other compounds |
-
2010
- 2010-03-12 EP EP16001044.3A patent/EP3075390A1/en not_active Withdrawn
- 2010-03-12 JP JP2012549978A patent/JP5786204B2/ja active Active
- 2010-03-12 WO PCT/US2010/027155 patent/WO2011090492A1/en active Application Filing
- 2010-03-12 AU AU2010343304A patent/AU2010343304B2/en not_active Ceased
- 2010-03-12 CA CA2787074A patent/CA2787074A1/en not_active Abandoned
- 2010-03-12 CN CN201080061420.0A patent/CN102725000B/zh active Active
- 2010-03-12 IN IN5101DEN2012 patent/IN2012DN05101A/en unknown
- 2010-03-12 EP EP10844115.5A patent/EP2525820B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3075390A1 (en) | 2016-10-05 |
| CN102725000A (zh) | 2012-10-10 |
| CN102725000B (zh) | 2015-10-07 |
| EP2525820B1 (en) | 2016-05-11 |
| JP5786204B2 (ja) | 2015-09-30 |
| CA2787074A1 (en) | 2011-07-28 |
| AU2010343304B2 (en) | 2013-06-20 |
| EP2525820A4 (en) | 2013-08-21 |
| AU2010343304A1 (en) | 2012-07-05 |
| JP2013516996A (ja) | 2013-05-16 |
| EP2525820A1 (en) | 2012-11-28 |
| WO2011090492A1 (en) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN05101A (enrdf_load_stackoverflow) | ||
| JOP20200213A1 (ar) | جزيئات رابطة لـ pd-1 وطرق استخدامها | |
| MY190771A (en) | Anti-pd-l1 antibodies and uses thereof | |
| WO2021055253A3 (en) | Anti-tnfr2 antibodies and methods of use | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
| MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
| MX2009010120A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. | |
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| EA201070596A1 (ru) | Гуманизированные антитела против tl1a | |
| EA030777B9 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| AU2018338418A1 (en) | Anti-HLA-A2 antibodies and methods of using the same | |
| MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
| NZ626610A (en) | Antibodies that bind csf1r | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
| IN2012DN01663A (enrdf_load_stackoverflow) | ||
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| NZ597611A (en) | Anti notch-1 antibodies | |
| TN2012000151A1 (en) | Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer | |
| NZ778490A (en) | Pd-1-binding molecules and methods of use thereof | |
| MY188871A (en) | Pd-1-binding molecules and methods of use thereof |